Study Design. Retrospective cohort analysis. Objective. The aim of the study was to identify medications that may potentially contribute to developing postoperative urinary retention (POUR) after lumbar spinal fusion procedures. Summary of Background Data. POUR is a concerning event that may occur after routine orthopedic surgery. The relation between intraoperative medications and POUR after lumbar spine surgery has not been well characterized. Methods. A prospectively maintained database of patients who underwent a primary single-level, minimally invasive transforaminal lumbar interbody fusion between 2009 and 2013 was reviewed. POUR was defined as a bladder scan of 300 mL or higher, the postoperative necessity of a straight catheterization, or a urology consult for urinary retention. The use and doseresponse of intraoperative medications between patients with and without POUR were compared. Potential risk factors for developing POUR were analyzed using multivariate analysis. Results. A total of 205 patients were included in the study, 17% of whom experienced POUR (n ¼ 34). Administration of phenylephrine and neostigmine was associated with POUR (phenylephrine: 32.3% vs. 13.8%, P ¼ 0.017; neostigmine: 19.5% vs. 6.5%, P ¼ 0.042). Parametric analysis demonstrated an association of increasing dose of neostigmine with POUR (4.66 vs. 4.22 mg, P ¼ 0.023). Similarly, a nonparametric analysis demonstrated an association of increasing doses of both neostigmine and phenylephrine with POUR (neostigmine: 4.25 vs. 3.16 mg, P ¼ 0.02; phenylephrine: 105.88 vs. 40.64 mg, P ¼ 0.008).
Study Design. Retrospective cohort analysis.
Objective. The aim of the study was to identify medications that may potentially contribute to developing postoperative urinary retention (POUR) after lumbar spinal fusion procedures. Summary of Background Data. POUR is a concerning event that may occur after routine orthopedic surgery. The relation between intraoperative medications and POUR after lumbar spine surgery has not been well characterized. Methods. A prospectively maintained database of patients who underwent a primary single-level, minimally invasive transforaminal lumbar interbody fusion between 2009 and 2013 was reviewed. POUR was defined as a bladder scan of 300 mL or higher, the postoperative necessity of a straight catheterization, or a urology consult for urinary retention. The use and doseresponse of intraoperative medications between patients with and without POUR were compared. Potential risk factors for developing POUR were analyzed using multivariate analysis. Results. A total of 205 patients were included in the study, 17% of whom experienced POUR (n ¼ 34). Administration of phenylephrine and neostigmine was associated with POUR (phenylephrine: 32.3% vs. 13.8%, P ¼ 0.017; neostigmine: 19.5% vs. 6.5%, P ¼ 0.042). Parametric analysis demonstrated an association of increasing dose of neostigmine with POUR (4.66 vs. 4.22 mg, P ¼ 0.023). Similarly, a nonparametric analysis demonstrated an association of increasing doses of both neostigmine and phenylephrine with POUR (neostigmine: 4.25 vs. 3.16 mg, P ¼ 0.02; phenylephrine: 105.88 vs. 40.64 mg, P ¼ 0.008).
Conclusion. Approximately 20% of patients may develop POUR after routine lumbar spine surgery. The use of certain intraoperative anesthetics such as phenylephrine and neostigmine is strongly associated with the development of POUR postoperatively. This finding suggests that there may be modifiable anesthetic risk factors to prevent the development of POUR in patients undergoing lumbar spine surgery. Future prospective, controlled studies specifically addressing these findings could lead to improved patient care and decreased healthcare costs. Key words: anesthesia, intraoperative medication, lumbar fusion, neostigmine, phenylephrine, postoperative urinary retention, urinary retention. Level of Evidence: 4 Spine 2016;41:1441-1446 P ostoperative urinary retention (POUR) is a concerning event that may contribute to patient discomfort and dissatisfaction. Given that POUR rates have been reported to be as high as 70% after certain orthopedic procedures, there is significant potential to improve patient care by reducing this incidence.
1-3 POUR often resolves without serious sequelae, although in rare instances it may lead to long-term bladder dysfunction. 1, 3 In addition to patient dissatisfaction, POUR has also been associated with extended length of hospitalization and greater healthcare costs. 2, 3 Despite the abundance of research regarding bladder function, the majority of the literature regarding POUR after orthopedic procedures has focused on the effects of general anesthesia for total joint arthroplasty. [4] [5] [6] The data are, however, limited in the context of spinal procedures. [7] [8] [9] Several studies have investigated POUR after spinal procedures. These studies have, however, focused on nonmodifiable demographic risk factors such as sex and age. Although it is important to understand all risk factors 
MATERIALS AND METHODS

Population
Institutional review board approval was obtained for this level III study. A retrospective review of prospectively collected data was performed. Consecutive patients having undergone single-level, minimally invasive primary transforaminal lumbar interbody fusion (TLIF) by a single surgeon during 2009 to 2013 were identified. Patients who underwent cervical surgeries, lumbar decompression only, multilevel surgery, or a revision TLIF were excluded from the analysis. Patients were considered to have POUR if postvoid residual volume was greater than or equal to 300 mL on bladder scan, straight catheterization was required postoperatively, or a urology consult was placed during their hospitalization.
Data Collection
Patients were stratified into one of two groups based on the presence or absence of POUR. Age, sex, comorbidities (Charlson Comorbidity Index, diabetes mellitus, and benign prostate hyperplasia [BPH]), operative time, operative levels, and quantity of intraoperative intravenous fluids were compared between patients with and without POUR. Perioperative medications were analyzed for association with the development of POUR; the medications included: narcotics (morphine, fentanyl, remifentanil), muscle relaxants (succinylcholine, rocuronium, vecuronium), reversal agents (neostigmine), vasopressors (phenylephrine), and inductive agents (methohexital). If a medication was given in less than 5% of patients it was not included in the analysis (e.g., intraoperative ondansetron for history of perioperative nausea). Lastly, patients with and without POUR were compared by length of hospitalization.
Statistical Analysis
Statistical analysis was conducted using Stata version 13.1 (College Station, TX). First, the rate of POUR was tested for association with demographic, comorbidity, and procedural characteristics using Student's t test (continuous characteristics) or Fisher exact test (binary characteristics). Second, the rate of POUR was tested for association with the administration of various anesthetic medications using Fisher exact test. Third, the dose of each medication was tested for association with the occurrence of POUR in both parametric (Fisher exact test, excluding patients who did not receive the medication) and nonparametric (Wilcoxon ranksum test, including patients who did not receive the medication) analyses. As a final step, each of these analyses was repeated stratified by male versus female sex.
RESULTS
Of the 205 patients included in the study, 34 (17%) experienced POUR. Bivariate analysis comparing patient demographics and preoperative characteristics between patients who did and did not experience POUR demonstrated no differences in regards to age, sex, Charlson Comorbidity Index, history of diabetes mellitus or BPH, operative level, operative time, or amount of intravenous fluids received (Table 1) . Table 2 reports associations of POUR with administration versus no administration of the evaluated medications. Patients who were administered phenylephrine and neostigmine had higher rates of POUR (phenylephrine, 32.3% vs. 13.8%, P ¼ 0.017; neostigmine, 19.5% vs. 6.5%, P ¼ 0.042). No other medications were associated with POUR (P > 0.05 for each). Table 3 reports associations of POUR with the dose of each medication administered. On the left is the parametric analysis, which excludes patients who did not receive the medication. In this analysis, the mean dose of neostigmine received by patients with POUR was higher than the mean dose of neostigmine received by other patients (4.66 vs. 4.22 mg, P ¼ 0.023). There were no other differences in the mean doses of medications between patients with and without POUR (P > 0.05 for each). On the right is the nonparametric analysis, which includes patients who did not receive the medication. In this analysis, the mean dose of neostigmine received by patients with POUR was higher than the mean dose of neostigmine received by other patients (4.25 vs. 3.16 mg, P ¼ 0.023). Similarly, the mean dose of phenylephrine received by patients with POUR was higher than the mean dose of phenylephrine received by other patients (105.88 vs. 40.64 mg, P ¼ 0.008).
In the analysis including only men (Appendix A, http:// links.lww.com/BRS/B129), the only association with POUR was older age (58.0 vs. 50.7 years, P ¼ 0.040). There were no associations of POUR with medication administration.
In the analysis including only women (Appendix B, http:// links.lww.com/BRS/B130), patients who were administered phenylephrine and neostigmine had higher rates of POUR (phenylephrine, 33.3% vs. 11.6%, P ¼ 0.031; neostigmine, 19.3% vs. 0.0%, P ¼ 0.037). In the nonparametric analysis, the mean dose of phenylephrine received by patients with POUR was higher than the mean dose of phenylephrine received by other patients (137.50 vs. 46.59 mg, P ¼ 0.019). Similarly, the mean dose of neostigmine received by patients with POUR was higher than the mean dose of neostigmine received by other patients (4.66 vs. 3.15, P ¼ 0.002).
Following adjustment for demographic, comorbidity, and operative characteristics, patients with POUR had longer hospital lengths of stay (mean difference ¼ 34.4 h, P < 0.001).
DISCUSSION
The current study suggests that common intraoperative medications may increase the risk of POUR. Despite a homogenous population of young patients with minimal comorbidities, POUR was present at a rate of 17%. Among the medications examined, phenylephrine and neostigmine presented as significant risk factors for the development of POUR. In addition, both medications demonstrated dosedependent effects on the incidence of POUR, as those who received higher doses of each were at elevated risk of POUR.
Phenylephrine is an alpha-receptor agonist that is commonly used to treat intraoperative hypotension through contraction of vascular smooth muscle. Although phenylephrine has not been directly examined as a cause of POUR, studies have suggested that alpha-receptor agonists promote urinary continence. 10, 11 The bladder neck is primarily innervated with alpha-1 receptors, which when stimulated cause smooth muscle constriction and an increased bladder outlet resistance. Knowing that selective alpha-1 antagonists such as terazosin, doxazosin, and alfuzosin are commonly used to treat patients suffering from both hypertension (HTN) and BPH, administration of an alpha-1 agonist such as phenylephrine for intraoperative HTN intuitively may also exacerbate urinary retention. In contrast to the previously mentioned medications, tamsulosin and silodosin are prostate-specific alpha-antagonists and are not first-line medications for patients suffering from both HTN and BPH; however, these medications may contribute to POUR if ingested. However, on review of patient medical records, equal proportions of patients with BPH taking medications such as those listed above did and did not experience POUR. Another potential mechanism of phenylephrine, as it pertains to POUR, may stem from its inhibitory effects on the parasympathetic reflex pathways innervating the genitourinary system. Specifically, the urethral sphincter muscles are activated while the detrusor muscle is relaxed, thus preventing bladder emptying. 12 Neostigmine is a medication used to reverse the effects of muscle relaxants. As an acetylcholinesterase inhibitor, it allows acetylcholine to accumulate at the neuromuscular junction. Activation of acetylcholine receptors has been established to promote bladder voiding. 13, 14 This is inconsistent with the results of this study, which suggested that neostigmine administration may be associated with the development of POUR. Potential explanatory pathologic mechanisms have, however, been proposed, including The nonparametric analysis includes patients who did not receive the medication.
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Anesthetic Medications on Postoperative Urinary Retention Mayo et al smooth muscle spasms from a cholinergic surge, partial agonist effects on muscarinic receptors, or deleterious effects from additives in neostigmine solutions such as glycopyrrolate, an anticholinergic, which may decrease bladder wall tone. [15] [16] [17] Previous studies have demonstrated a wide range of risk factors for POUR. [7] [8] [9] 18 In a prospective randomized trial, McNeill et al reported a POUR rate of 39% in patients undergoing either lumbar laminectomies or discectomies who received epidural administration of pain medications. Despite this high rate, the epidural administration of morphine, steroids, or both did not result in a significantly higher rate of POUR when compared with placebo (50% vs. 35%, P ¼ 0.25). 19 This study was, however, limited by examining only postoperative medications, while excluding those administered intraoperatively. In addition, the postoperative medications were restricted to epidural morphine and steroids in this particular study.
In a series of 503 patients, Boulis et al 7 reported on the risk factors for POUR after cervical and lumbar procedures. In this study, the rate of POUR was 38%, whereas advanced age and preoperative beta-blocker consumption were identified as risk factors. Although somewhat counterintuitive, narcotic medications were protective against POUR. Similarly, it has been reported that neural decompression techniques and the associated neural manipulation may lead to an increased risk for POUR. As we are unable to quantify the extent of neural manipulation sustained throughout an operation, efforts to reduce procedural variability and the associated neural manipulation were accomplished by having a single surgeon at a single academic institution perform all procedures. In addition, all patients underwent a minimally invasive TLIF with some form of direct decompression such as laminectomy, facetectomy, osteotomy, or foraminotomy and only 17% of the patient population experienced POUR. Jung et al 9 reported a POUR rate of 11.1% after anterior cervical spine surgery. Major risk factors included male sex, advanced age, BPH, myelopathy, and the use of meperidine. Both studies suggested that the incidence of POUR may be associated with longer length of hospitalization. These previous studies were, however, limited in their methodology by focusing primarily on postoperative pain medications as opposed to a variety of intraoperative medications.
In the largest series regarding POUR in spine surgery, Gandhi et al 8 reviewed 647 patients undergoing lumbar procedures. The authors reported a 5.0% POUR rate, identifying male sex, benign prostatic hyperplasia, older age, diabetes, and depression as risk factors (odds ratio 3.05, 9.82, 1.04, 3.32, 2.51, respectively).
Many intuitive risk factors such as diabetes, older age, benign prosthetic hyperplasia, longer operative time, and high intravenous fluid administration were not demonstrated as significant risk factors in the present study. As such, this study may have been underpowered to identify some of these demographic associations.
There were limitations to the current study. First, manipulation of the sacral nerve roots or formation of a small epidural hematoma may contribute to bladder dysfunction without being clinically identifiable. Manipulation of the sacral nerve is, however, generally nominal in a minimally invasive TLIF, as the tubular dilator is positioned laterally over the transforaminal space. Second, it is possible that some patients had subclinical dysfunction of the genitourinary system, which may not have been adequately delineated before surgery, and thus placing them at higher risk for development of POUR. Third, of the 15 women who experienced POUR, 4 patients previously underwent hysterectomy, 2 patients underwent benign abdominal cyst or ovarian removal, 1 patient had underwent a partial colectomy and subsequent scar tissue removal years later, 2 patients underwent bladder suspension surgery, and 1 patient experienced preoperative urinary retention. Although these patients may have scar tissue or alternative issues contributing to urinary retention, only one of these women complained of incomplete voiding and urinary irregularity before the operation. Finally, in the context of the homogeneity of patients in this study (only one type of spinal surgery was investigated, and all surgeries were performed by one surgeon at one location), these findings may not be generalizable to other patient populations.
CONCLUSION
Approximately one in five patients develops POUR after an uncomplicated primary, single-level minimally invasive TLIF surgery. The administration of phenylephrine and neostigmine was significant risk factor associated with the development of POUR. The results of the current study suggest that specific anesthetic techniques may be modified to reduce the risk for POUR in patients undergoing lumbar spine surgery. Future prospective, controlled studies specifically designed to mitigate the risk of POUR could lead to improved patient care, decreased length of hospitalization, and reduced healthcare-related costs.
Key Points
Nearly one in five patients develops urinary retention after lumbar spine surgery. Higher rates of urinary retention can be observed in patients with benign prostatic hyperplasia or who have received phenylephrine or neostigmine intraoperatively. Although phenylephrine demonstrated a dosedependent effect on urinary retention, the use of neostigmine demonstrated the greatest relative risk for urinary retention on multivariate analysis.
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